AHA 25 Late-breaking Discussion: Comparison from the TUXEDO-2 Trial

17 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
AHA 2025 — late-breaker host Dr Harriette Van Spall (McMaster University, CA) was joined by the TUXEDO-2 Principal Investigator, Dr Sripal Bangalore to present the findings of this late-breaking randomized trial comparing ticagrelor versus prasugrel in patients with diabetes mellitus and multivessel coronary artery disease undergoing percutaneous coronary intervention (PCI).

Conducted across multiple centers in India, TUXEDO-2 randomized approximately 1800 patients to recieve either ticagrelor or prasugrel in combination with aspirin. The primary endpoint was a composite of death, non-fatal myocardial infarction, stroke and major bleeding.

The study found that in patients with multivessel disease undergoing PCI, ticagrelor did not meet non-inferiority compared to prasugrel when added to aspirin as part of dual antiplatelet therapy.

For more content from AHA 2025 head to the Late-breaking Science Video Collection.

Editor: Mirjam Boros, Jordan Rance
Videographer: Oliver Miles

Support: This is an independent video produced by Radcliffe Cardiology.

Visit Radcliffe Cardiology: https://www.radcliffecardiology.com/

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook: https://www.facebook.com/RadcliffeCardiology
Follow us on X: https://x.com/radcliffeCARDIO
Categoria
Cardiology
Commenta per primo questo video.

Prossimo